Role of Molecular Factors in BMI, Endometrial Cancer Link Studied
TUESDAY, April 19, 2022 (HealthDay News) — Molecular traits may mediate the relationship...
Read More
Search Results for: endometrial cancer
Lenvatinib plus pembrolizumab increased survival for advanced endometrial cancer patients when compared to chemotherapy
1. The median progression-free survival and overall survival was longer with lenvatinib plus pembrolizumab than with chemotherapy. 2. Clinically important adverse events in the combination group included hypertension, thyroid dysfunction, colitis and diarrhea Evidence Rating Level: 1 (Excellent) Study Rundown: Advanced endometrial cancer after platinum treatment remains difficult to treat and fiver-year survival remains poor. […]
Read MoreIdentifying and Managing the Unfavourable Feedbacks in Advance Endometrial Cancer Patients Who Were Treated with Lenvatinib Plus Pembrolizumab
Treating advanced endometrial cancer (which is not deficient in MMR or high in microsatellite instability) with a mixture of lenvatinib and pembrolizumab has been effective and successful after the patient received earlier...
Read MoreAdditional Treatment for Endometrial Cancer During its Early-Stages in the U.S.
As the most widely recognized gynecologic danger in the United States of America, endometrial cancer has a growing occurrence that is most likely subordinate only to the obesity epidemic. For endometrial cancer in its early...
Read MoreCase Study on a MMR-Deficient Endometrial Cancer Patient with BRCA1 Mutation Who Entered Remission After Being Administered With Pembrolizumab
Endometrial cancer is the most widely recognized gynecologic danger in the United States of America. Even though the majority of endometrial cancer cases present are at the beginning phases, the patients who are diagnosed with...
Read More